BCAX - Latest News
Bicara Therapeutics Inc. Common Stock (BCAX), operates in Healthcare / Biotechnology, trades on NASDAQ.
Market capitalization stands near $1.47B. Beta to the broader market is -0.53.
The article list below shows the most recent BCAX headlines from major financial news vendors. For options traders, the most actionable items are earnings releases, analyst rating changes, M&A activity, and regulatory filings - each can drive a meaningful repricing of implied volatility and shift dealer hedging flow. Pair the news context with the implied-volatility skew and gamma exposure views to see whether the options market has already priced in the headline.
Recent BCAX Headlines
What Does the Bicara Therapeutics CEO's Sale of 15,000 Shares Mean for Investors?
fool.com - Jun 13, 2026
CEO Claire Mazumdar sold 15,000 shares for a transaction value of approximately ~$301,000, based on a weighted average price of around $20. 04 per sha
Bicara Therapeutics Inc. (BCAX) Discusses New Clinical Data on Investigational Therapy for HPV Negative Head and Neck Cancer at ASCO Transcript
seekingalpha.com - May 22, 2026
Bicara Therapeutics Inc.
Bicara Therapeutics ASCO Data Bolster Ficerafusp Alfa in Head and Neck Cancer
marketbeat.com - May 22, 2026
Bicara Therapeutics NASDAQ: BCAX said new data to be presented at the 2026 American Society of Clinical Oncology annual meeting support the clinical p
Ficerafusp Alfa Plus Pembrolizumab Demonstrated Differentiated Three-Year Overall Survival and Deep Responses Driven by TGF-β Inhibition in 1L R/M HPV-Negative HNSCC
globenewswire.com - May 21, 2026
At a median follow-up of three years, 1500mg of ficerafusp alfa weekly in combination with pembrolizumab demonstrated an estimated 31% overall surviva
Bicara Stock Is Up 50%, and One Biotech Investor Has Made It a 29% Portfolio Bet
fool.com - May 15, 2026
This clinical-stage biotech develops bifunctional antibody therapies targeting solid tumors for oncology providers and institutions.
How News Affects BCAX Options Pricing
Headlines and scheduled events drive implied volatility in two distinct ways. Pre-event, IV typically inflates as uncertainty about the outcome rises; this is the implied-volatility expansion that creates the long-vol setup. Post-event, IV typically contracts sharply as uncertainty resolves; this is IV crush, which makes premium-selling structures profitable when they survive the underlying move. The size of the crush depends on how stretched pre-event IV is relative to the realized move. Track BCAX's implied vs realized volatility over the news cycle to size pre-event vs post-event positioning. For ticker-level dealer positioning context, the gamma exposure view shows whether dealers are positioned to amplify or dampen post-news moves.
Frequently asked BCAX news questions
- What is the latest BCAX news headline?
- The most recent BCAX headline (Jun 13, 2026) is "What Does the Bicara Therapeutics CEO's Sale of 15,000 Shares Mean for Investors?". The five most recent stories with summaries and publication times are listed above, sourced from major financial news vendors.
- How fresh is the BCAX news on this page?
- News rows refresh roughly every 30 minutes during the trading day. The five most recent headlines are listed in publication-time order. Press releases from the company itself typically appear within minutes of the wire release; third-party reporting may lag by 30-60 minutes depending on the source.
- What BCAX news moves options pricing?
- Three categories move single-name IV most aggressively: scheduled earnings releases (priced into pre-event IV, crushed post-event), unscheduled M&A or strategic announcements (rapid IV expansion, slower decay), and regulatory or legal events (drug-trial readouts, antitrust filings, FDA approvals). Routine news flow (analyst commentary, sector rotation) typically does not move IV meaningfully unless it triggers a cluster of rating changes.
- How can I track unusual BCAX options activity related to news?
- Unusual options activity often precedes news by hours to days; the canonical signals are volume substantially above the trailing average concentrated in a small number of strikes, atypical put/call skew, and aggressive execution (at-the-ask sweeps or block prints). Cross-reference the per-ticker gamma-exposure and volume-history pages with the news flow above to triangulate informed vs uninformed flow.